Column

Engaging Payers

Building Episodes of Care Models for Oncology & Other Chronic Conditions

03/16/2020

The episodes of care payment model is designed to put the patient at the center of care delivery, with their care coordinated among all providers for more comprehensive care to achieve the best possible outcomes....

The...

03/16/2020

Journal of Clinical Pathways

Clinical Pathways GPS

Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease

03/16/2020

Matthew Pakizegee , PharmD, MS;

Jonathan W. Hodgson , MBA;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Chad McAuliffe ;

Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...

...

03/16/2020

Journal of Clinical Pathways

Editor's Page

Real-World Use of Value-Based Tools and Tracking Outcomes

02/18/2020

Winston Wong , PharmD;

High-quality tools have the ability to utilize sophisticated digital mechanisms to improve patient outcomes while also enhancing data collection, lowering costs, and increasing accountability. Clinical pathways and...

...

02/18/2020

Journal of Clinical Pathways

Trending From ACCC

2019 ACCC Survey Respondents Recognize Care Standardization as Opportunity for Cost Savings

02/18/2020

JCP Editors

In January, the Association of Community Cancer Centers (ACCC) released results of the “2019 Trending Now in Cancer Care Survey.” This marks the 10th year of the annual ACCC survey, which is designed to identify...

In...

02/18/2020

Journal of Clinical Pathways

Pharma Insights

Where Will Health Care Take Us in the 2020s?

02/18/2020

David B. Carr , PhD, MD, CMD;

Larry Blandford , PharmD;

As we say goodbye to the 2010s, we look at the prevailing trends and project forward to what we think are the key topics to consider in the coming decade—not an easy task. Looking back at commentary and predictions...

As we...

02/18/2020

Journal of Clinical Pathways

Clinical Pathways GPS

Clinical Pathways and Policy to Guard Against Misaligned Incentives

02/18/2020

Seth Gordon , MBA;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization...

The...

02/18/2020

Journal of Clinical Pathways

PATIENT PERSPECTIVE

A Framework for Person-Centered Care Pathways in Oncology

02/18/2020

Alan J. Balch , PhD, MSc;

Historically, the development of clinical pathways has been effective in treatment planning for cancer care. In line with the increasing sophistication of pathways, it is time to consider how patient-specific factors...

...

02/18/2020

Journal of Clinical Pathways

Counterpoint

Are We Really Measuring Quality?

12/17/2019

Winston Wong , PharmD;

Dr Wong responds to the Viewpoint by Dr Valuck and colleagues, contemplating and evaluating the current quality measures used in care today. He asserts that, rather than trying to develop, revise, and modify quality...

Dr...

12/17/2019

Journal of Clinical Pathways

Viewpoint

Catch Me If You Can: Aligning Quality Measurement With Oncology Innovation

12/17/2019

Tom Valuck , MD, JD;

Theresa Schmidt , MA, PMP, CSPO;

David Blaisdell , BA;

Breakthrough treatments in cancer care, including precision therapies tailored to specific patient factors, are driving rapid changes in the definitions of oncology quality and value. Efforts to implement value-based...

...

12/17/2019

Journal of Clinical Pathways

Business of Pathways

Health Care as a Preexisting Financial Condition: Individual Costs and Societal Benefits

12/17/2019

Ira Klein , MD, MBA, FACP;

Sean McElligott , MS;

While societally we are still debating the best way to finance health care, we do all agree that when a therapy is available to alleviate illness and suffering, we should find a way to make it available to patients....

While...

12/17/2019

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products